In support of these findings, it has been reported that certain dual targeted PI3K/mTOR inhibitors efficiently killed primary c-Myc-driven B-cell lymphomas and human cell lines bearing IG-c-Myc translocations [54]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.